Physician profile
Lane Benoff
NPI 1073581997
$7,243.92
in general payments reported to CMS, 2019-2025
29 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $310 · 2021: $1,175 · 2022: $1,305 · 2023: $1,383 · 2024: $1,301 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $1,369.75 | 2020-2025 | Nexletol |
| Amgen INC. | $936.04 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $808.03 | 2019-2025 | |
| Boston Scientific Corporation | $629.86 | 2019-2025 | Watchman Flx, Watchman |
| Medtronic, INC. | $626.15 | 2022-2025 | Micra, Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.05 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $410.60 | 2019-2023 | |
| Philips North America LLC | $345.69 | 2023-2025 | Mcot, (Ck7) Extended Holter |
| Heartflow, INC. | $256.15 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.71 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $193.75 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.15 | 2023 | Lifevest |
| Pfizer INC. | $123.66 | 2021-2025 | |
| Cvrx, INC. | $88.01 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $80.73 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.86 | 2021-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $65.65 | 2019-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $64.61 | 2020-2022 | |
| Baxter Healthcare | $46.01 | 2023 | Hillrom - Eli 380 |
| Bardy Diagnostics, INC. | $35.00 | 2019-2020 | |
| Chiesi USA, INC. | $29.24 | 2019 | |
| Abbott Laboratories | $21.80 | 2025 | Aveir |
| Irhythm Technologies, INC. | $16.94 | 2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $16.57 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals, Ltd. | $16.27 | 2023 | Arcalyst |
| W. L. Gore & Associates, INC. | $14.94 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.51 | 2024 | |
| Lilly USA, LLC | $13.13 | 2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Benoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.